SUMM Summit Therapeutics Plc

 
TIDMSUMM 
 
   Summit Therapeutics plc 
 
   ("Summit" or the "Company") 
 
   EXERCISE OF SHARE OPTIONS 
 
   Oxford, UK, 24 October 2016 - Summit Therapeutics plc (AIM: SUMM, 
NASDAQ: SMMT), the drug discovery and development company advancing 
therapies for Duchenne muscular dystrophy and C. difficile infection, 
announces that, following the exercise of employee share options, the 
Company has issued 11,000 new ordinary shares of 1p each (the "New 
Ordinary Shares"). 
 
   Application has been made for the admission to trading on AIM of the New 
Ordinary Shares, which will rank pari passu with the Company's existing 
ordinary shares, and admission is expected to occur on or around 28 
October 2016. 
 
   Following admission of the New Ordinary Shares to trading on AIM, the 
total number of ordinary shares with voting rights in issue will be 
61,815,316.  This figure may be used by shareholders as the denominator 
for the calculations by which they will determine if they are required 
to notify their interest in, or a change to their interest in, the 
Company under the FCA's Disclosure and Transparency Rules. 
 
   This announcement contains inside information for the purposes of 
Article 7 of EU Regulation 596/2014. 
 
   - END - 
 
   For more information, please contact: 
 
 
 
 
Summit Therapeutics 
 Richard Pye (UK office)         Tel: +44 (0)1235 443 951 
 Erik Ostrowski (US office)      +1 617 294 6607 
Cairn Financial Advisers LLP 
 (Nominated Adviser)             Tel: +44 (0)20 7213 0880 
 Liam Murray / Tony Rawlinson 
 
 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Summit Therapeutics plc via Globenewswire 
 
 
  http://www.summitplc.com/ 
 

(END) Dow Jones Newswires

October 24, 2016 11:23 ET (15:23 GMT)

Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Mar 2024 to Apr 2024

Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Apr 2023 to Apr 2024